Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists



  1. 1.
    Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–317CrossRefPubMedGoogle Scholar
  2. 2.
    Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363–375CrossRefPubMedGoogle Scholar
  3. 3.
    Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354–362CrossRefPubMedGoogle Scholar
  4. 4.
    Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P-450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19):2553–2560CrossRefPubMedGoogle Scholar
  5. 5.
    CURE Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494–502CrossRefGoogle Scholar
  6. 6.
    Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Duke University School of MedicineDurhamUSA

Personalised recommendations